A 6-MONTH, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER, PARALLEL GROUP, MAINTENANCE OF EFFECT STUDY OF ESREBOXETINE (PNU-165442G) ADMINISTERED ONCE DAILY (QD) IN PATIENTS WITH FIBROMYALGIA

Update Il y a 4 ans
Reference: EUCTR2008-006760-10

Woman and Man

  • | Country :
  • -
  • | organs :
  • -
  • | Specialty :
  • -

Extract

To evaluate the efficacy of ESRBX (QD) compared with placebo treatment in assessing the maintenance of effect for the treatment of pain intensity and function associated with fibromyalgia.


Inclusion criteria

  • Esreboxetine is being developed for the treatment of fibromyalgia

Links